DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Natalizumab - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Immunomodulatory Agents

Dosage Forms

  • Solution (IV Infusion)

Brands / Synonyms

Anti-alpha4 integrin; Anti-VLA4; Tysabri; Tysabri (Antegren) Biogen & Elan Corp

Description

Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin

Indications

For treatment of multiple sclerosis

Pharmacology

In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain.

Mechanism of Action

Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).

Absorption

Not Available

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to leukocytes.

Contraindications

Not Available

Drug Interactions

Not Available

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015